First Header Logo Second Header Logo

Connection

Steven Feldman to Double-Blind Method

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about Double-Blind Method.
Steven Feldman
Connection Strength
2.265
Double-Blind Method
  1. Huang WW, Feldman SR. The next quantum leap forward? Bimekizumab for psoriasis. Lancet. 2021 02 06; 397(10273):446-448.
    View in: PubMed
    Score: 0.170
  2. Gadarowski MB, Ghamrawi RI, Taylor SL, Feldman SR. PrabotulinumtoxinA-xvfs for the Treatment of Moderate-to-Severe Glabellar Lines. Ann Pharmacother. 2021 03; 55(3):354-361.
    View in: PubMed
    Score: 0.164
  3. Mendes JT, Balogh EA, Strowd LC, Feldman SR. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis. Expert Opin Pharmacother. 2020 Jun; 21(9):1027-1033.
    View in: PubMed
    Score: 0.160
  4. Patel NU, Grammenos A, Gowda A, Onikoyi O, Feldman SR. 4-Day evaluation of the irritation potential of topical desoximetasone 0.25% and 0.05% spray on light-exposed skin. J Dermatolog Treat. 2018 Jun; 29(4):415-417.
    View in: PubMed
    Score: 0.136
  5. Oussedik E, Saleem MD, Feldman SR. A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation. J Drugs Dermatol. 2017 Oct 01; 16(10):972-975.
    View in: PubMed
    Score: 0.135
  6. Feldman SR, Green L, Kimball AB, Siu K, Zhao Y, Herrera V, Nyirady J, Alexis AF. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017 Dec; 28(8):716-721.
    View in: PubMed
    Score: 0.134
  7. Nadkarni A, Saleem MD, Feldman SR. Topical Desoximetasone 0.25% Spray and Its Vehicle Have Little Potential for Irritation or Sensitization. J Drugs Dermatol. 2017 Aug 01; 16(8):755-758.
    View in: PubMed
    Score: 0.133
  8. Saleem MD, Negus D, Feldman SR. Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial. J Dermatolog Treat. 2018 Feb; 29(1):32-35.
    View in: PubMed
    Score: 0.132
  9. Feldman SR, Winkelman W, Baum E, Preston N. Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray. J Drugs Dermatol. 2013 Dec; 12(12):1456-60.
    View in: PubMed
    Score: 0.104
  10. Akamine KL, Gustafson CJ, Yentzer BA, Edison BL, Green BA, Davis SA, Feldman SR. A double-blind, randomized clinical trial of 20% alpha/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis. J Drugs Dermatol. 2013 Aug; 12(8):855-9.
    View in: PubMed
    Score: 0.101
  11. Feldman SR, Werner CP, Alió Saenz AB. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013 Apr; 12(4):438-46.
    View in: PubMed
    Score: 0.099
  12. Feldman SR, Mills M, Brundage T, Eastman WJ. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. J Drugs Dermatol. 2013 Mar; 12(3):300-6.
    View in: PubMed
    Score: 0.098
  13. Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Am J Clin Dermatol. 2012 Aug 01; 13(4):261-71.
    View in: PubMed
    Score: 0.094
  14. Krejci-Manwaring J, McCarty MA, Camacho F, Manuel J, Hartle J, Fleischer A, Feldman SR. Topical tacrolimus 0.1% improves symptoms of hand dermatitis in patients treated with a prednisone taper. J Drugs Dermatol. 2008 Jul; 7(7):643-6.
    View in: PubMed
    Score: 0.071
  15. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol. 2006 Jun; 5(6):527-32.
    View in: PubMed
    Score: 0.062
  16. Kaur M, Liguori A, Fleischer AB, Feldman SR. Plasma beta-endorphin levels in frequent and infrequent tanners before and after ultraviolet and non-ultraviolet stimuli. J Am Acad Dermatol. 2006 May; 54(5):919-20.
    View in: PubMed
    Score: 0.061
  17. Kaur M, Liguori A, Lang W, Rapp SR, Fleischer AB, Feldman SR. Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. J Am Acad Dermatol. 2006 Apr; 54(4):709-11.
    View in: PubMed
    Score: 0.061
  18. Kirkland CR, Yelverton CB, Fleischer AB, Camacho FT, Feldman SR. Gel vehicles are not inherently more irritating than creams. J Drugs Dermatol. 2006 Mar; 5(3):269-72.
    View in: PubMed
    Score: 0.060
  19. Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005 Nov; 53(5):887-9.
    View in: PubMed
    Score: 0.059
  20. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB, Feldman SR. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol. 2003 Jul; 49(1):79-82.
    View in: PubMed
    Score: 0.050
  21. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002 May; 41(5):269-74.
    View in: PubMed
    Score: 0.046
  22. Ramachandran V, Cline A, Feldman SR, Strowd LC. Evaluating crisaborole as a treatment option for atopic dermatitis. Expert Opin Pharmacother. 2019 Jun; 20(9):1057-1063.
    View in: PubMed
    Score: 0.038
  23. Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, Draelos Z, Mamolo C, Purohit V, Wang C, Ports WC. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol. 2016 10 03; 16(1):15.
    View in: PubMed
    Score: 0.032
  24. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
    View in: PubMed
    Score: 0.020
  25. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan; 56(1):31.e1-15.
    View in: PubMed
    Score: 0.016
  26. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.
    View in: PubMed
    Score: 0.014
  27. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004 Nov; 51(5):723-30.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.